Last reviewed · How we verify
NCT06690970
Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
trial testing 68Ga/18F-PSMA/PSFA in PSMA-related Disease in 500 participants. Currently enrolling.
1 December 2027
Quick facts
| Lead sponsor | Tianjin Medical University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 September 2020 |
| Primary completion | 1 December 2027 |
| Estimated completion | 1 December 2027 |
| Sites | 2 locations across China |
Drugs / interventions tested
- 68Ga/18F-PSMA/PSFA
Conditions studied
- PSMA-related Disease — all drugs for PSMA-related Disease →
- Prostate Cancer — all drugs for Prostate Cancer →
- Positron Emission Tomography — all drugs for Positron Emission Tomography →
- Metastasis — all drugs for Metastasis →
Sponsor
Tianjin Medical University
Who can join
Adults 18 to 80, any sex, with PSMA-related Disease or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Preclinical evaluation and first-in-human study of <sup>68</sup>Ga- and Al<sup>18</sup>F-Labeled PSMA/FAP bispecific tracers for prostate cancer imaging.
Wang X, Wang M, Chen Y, Jian R, et al · · 2026 · cited 2× · PMID 41120594 · DOI 10.1007/s00259-025-07591-7
Verify or expand the search:
- PubMed search for NCT06690970
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Tianjin Medical University trials
Trials by the same sponsor.
- NCT07393685 — Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD · not yet recruiting
- NCT07306598 — [18F]NIDF PET Imaging in Tau-related Diseases · recruiting
- NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
- NCT06949670 — Alpha-Synuclein PET/CT in Various α-Syn-Related Disease · recruiting
- NCT06628531 — ALI & Pulmonary HA Deposition After SAH · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06690970 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University
- Last refreshed: 11 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06690970.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing